CL2014001126A1 - Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. - Google Patents
Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec.Info
- Publication number
- CL2014001126A1 CL2014001126A1 CL2014001126A CL2014001126A CL2014001126A1 CL 2014001126 A1 CL2014001126 A1 CL 2014001126A1 CL 2014001126 A CL2014001126 A CL 2014001126A CL 2014001126 A CL2014001126 A CL 2014001126A CL 2014001126 A1 CL2014001126 A1 CL 2014001126A1
- Authority
- CL
- Chile
- Prior art keywords
- stec
- immunogenic
- protein
- escherichia coli
- shigatoxins
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title 2
- 101710116435 Outer membrane protein Proteins 0.000 title 1
- 108010017898 Shiga Toxins Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 abstract 3
- 208000019331 Foodborne disease Diseases 0.000 abstract 1
- 108010079723 Shiga Toxin Proteins 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Existen distintas cepas de Escherichia coli que producen shigatoxina (STEC), asociados a enfermedades transmitidas por alimentos, y que pueden producir Síndrome Urémico Hemolítico (SUH). La invención corresponde a antígenos como vacunas, que son reconocidas por suero de pacientes que cursaron con SUH y reconocidas tanto por IgG como IgA.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2014001126A CL2014001126A1 (es) | 2014-04-29 | 2014-04-29 | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. |
| PCT/CL2015/000026 WO2015164989A1 (es) | 2014-04-29 | 2015-04-24 | Proteínas bacterianas inmunogénicas, composiciones farmacéuticas que las contienen, y vacunas contra escherichia coli productor de shigatoxinas |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2014001126A CL2014001126A1 (es) | 2014-04-29 | 2014-04-29 | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001126A1 true CL2014001126A1 (es) | 2014-08-29 |
Family
ID=52002355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001126A CL2014001126A1 (es) | 2014-04-29 | 2014-04-29 | Composición farmacéutica útil como vacuna contra bacterias escherichia coli productoras de shigatoxinas (stec), que comprende al menos un antígeno o una proteína de membrana externa inmunogénica o proteína inmunogénica asociada y conservada en cepas stec. |
Country Status (2)
| Country | Link |
|---|---|
| CL (1) | CL2014001126A1 (es) |
| WO (1) | WO2015164989A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020240268A1 (en) * | 2019-05-31 | 2020-12-03 | Universidad De Chile | An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002355074A (ja) * | 2001-01-24 | 2002-12-10 | Univ Tsukuba | 腸管出血性病原性大腸菌o157:h7に特異的な核酸分子およびポリペプチド並びにこれらの使用方法 |
| EP1580195A1 (en) * | 2004-03-26 | 2005-09-28 | Mutabilis SA | Compositions of polypeptides specific to pathogenic ExPEC E. coli strains and their use as vaccines and in immunotherapy |
| SI2351772T1 (sl) * | 2005-02-18 | 2016-11-30 | Glaxosmithkline Biologicals Sa | Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso |
| US20120263724A1 (en) * | 2005-04-20 | 2012-10-18 | Manohar John | Escherichia coli o157:h7 proteins and uses thereof |
| EP2586790A3 (en) * | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| GB0720250D0 (en) * | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| EP2417165B1 (en) * | 2009-04-06 | 2016-05-25 | University Of Saskatchewan | Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection |
| ES2662716T3 (es) * | 2009-07-07 | 2018-04-09 | Glaxosmithkline Biologicals Sa | Inmunógenos conservados de Escherichia coli |
| GB0917002D0 (en) * | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
-
2014
- 2014-04-29 CL CL2014001126A patent/CL2014001126A1/es unknown
-
2015
- 2015-04-24 WO PCT/CL2015/000026 patent/WO2015164989A1/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015164989A1 (es) | 2015-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
| MX2022010376A (es) | Polipeptidos efectores de la subunidad a de la toxina shiga desinmunizada para aplicaciones en mamiferos. | |
| NI201800052A (es) | Anticuerpos que neutraliza el virus respiratorio sincitial humano | |
| TR201908550T4 (tr) | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. | |
| EP4477662A3 (en) | Nucleic acid molecules and uses thereof | |
| BR112012022800A2 (pt) | composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica | |
| EA201691478A1 (ru) | Новый полисахарид и его применения | |
| BR112012008338A2 (pt) | combinação de vacinas contra doenças do trato respiratório. | |
| MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| EP4043031A3 (en) | Zika viral antigen constructs | |
| BR112014032636A2 (pt) | Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas | |
| CY1119957T1 (el) | Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος | |
| EA201891124A2 (ru) | Новые мукозные адъюванты и системы доставки | |
| CL2017000625A1 (es) | Composiciones de glicoconjugado inmunogénico/terapéutico y sus usos | |
| MX384875B (es) | Método para obtener una vacuna de mycoplasma. | |
| PH12015501716A1 (en) | Anti-mycoplasma spp. subunit vaccine | |
| MX2015011487A (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
| PH12015502844A1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
| BR112015023738B8 (pt) | Vacinas de nucleoproteina influenza | |
| BR112016006210A2 (pt) | terapia e vacina contra gripe | |
| MX2016013277A (es) | Vacuna para estreptococo de grupo a. | |
| BR112014020025A2 (pt) | vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas | |
| MX2022007577A (es) | Vacuna contra criptosporidiosis. | |
| WO2013173256A3 (en) | New and improved influenza vaccines | |
| AR087811A1 (es) | Vacuna contra el staphylococcus aureus |